Skip to main content
  • Register
  • Help
  • Contact us

Bavarian Nordic posts positive pre-clinical trial data for Covid-19 vaccine

Mon 08 March 2021 13:11 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Shares in Bavarian Nordic surged at the start following the release of positive pre-clinical trial data for its Covid-19 vaccine candidate, ABNCoV2.

The Danish biotechnology outfit said follow-up data from the study on its capsid virus like particle vaccine had confirmed that it induced neutralising antibodies against SARS-CoV-2, the virus responsible for Covid-19.

Indeed, the two high dose regimen without adjuvant, or boosters, triggered a greater than 50-fold increase in antibody levels in comparison to convalescent human samples.

Furthermore, when "challenged" with SARS-Cov-2, virus load was significantly reduced in all vaccinated groups and "no virus could be detected at any timepoint in the majority of the subjects vaccinated with two high doses of ABNCoV2."

As of 1446 GMT, shares of Bavarian Nordic were trading up by 7.43% to DKK217, having earlier in the session come within a whisker of its more than three-year highs of DKK261.0, after surging to DKK247.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More company news from ShareCast